Company Profile
United Therapeutics Stock Price, News & Catalysts
- Ticker:
- UTHR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
512.88 USD (-0.05%)
Close
Last updated: August 24, 2026
22.9B USD
Market cap
Why the stock is moving
As of Aug 24, 2026, UTHR was little changed and closed at $512.88. No new same-company headline was identified in the current news window.
Company overview
Business overview
United Therapeutics is a biotechnology company focused on therapies for pulmonary arterial hypertension and other severe chronic conditions. Its business has long been anchored by a small number of highly differentiated commercial products and a pipeline aimed at expanding that footprint.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, United Therapeutics has a U.S.-centered commercial and development profile. It sits in specialty biotech with a strong rare-disease and pulmonary-hypertension identity.
Business Model Characteristics
The company combines commercial product revenue with pipeline expansion, manufacturing discipline, and long-duration disease management. Investors watch product demand, label breadth, and whether the company can continue extending its franchise into new pulmonary indications.
Position Within the Biotechnology Landscape
United Therapeutics occupies a premium niche within biotech because it has already proved it can commercialize highly specialized therapies. It remains catalyst-sensitive, but the business is more durable than a pure early-stage biotech name.
Future catalysts
- United Therapeutics’ next catalysts are Tyvaso DPI growth, pulmonary-hypertension expansion, and any additional inhaled-treprostinil data. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of United Therapeutics (UTHR)?
United Therapeutics (UTHR) most recently closed at 512.88 USD, a -0.05% move versus the previous session.
What is the market cap of United Therapeutics (UTHR)?
United Therapeutics currently has a market capitalization of 22.9B USD on BioPharmSignal.
What does United Therapeutics do?
United Therapeutics is a biotechnology company focused on therapies for pulmonary arterial hypertension and other severe chronic conditions. Its business has long been anchored by a small number of highly differentiated commercial products and a pipeline aimed at expanding that footprint.
On which exchange is UTHR stock listed?
United Therapeutics (UTHR) is associated with NASDAQ, United States, Biopharma.
What is United?
United Therapeutics’ next catalysts are Tyvaso DPI growth, pulmonary-hypertension expansion, and any additional inhaled-treprostinil data.
Which conditions is United Therapeutics targeting with United?
United Therapeutics’ next catalysts are Tyvaso DPI growth, pulmonary-hypertension expansion, and any additional inhaled-treprostinil data.
How does United Therapeutics describe recent progress with United?
United Therapeutics’ next catalysts are Tyvaso DPI growth, pulmonary-hypertension expansion, and any additional inhaled-treprostinil data.
What is Therapeutics?
United Therapeutics is a biotechnology company focused on therapies for pulmonary arterial hypertension and other severe chronic conditions.